About
Results oriented business strategist and operator with success in executing business…
Activity
2K followers
-
Joshua S. Lev reposted thisJoshua S. Lev reposted thisToday on the main stage at #HLTHEurope, we launched #TheShift, a new #Women’sHealth series created for #HLTHEurope by #BBC StoryWorks. The #BBC series brings to life powerful, real-world patient and clinician's stories, making visible what has too often been overlooked: that women's health is about population health for the 51%, and we got to address it now. The BBC series reminded us that progress starts with listening differently to patients, designing differently, and acting with greater ambition as well as humanity. Innovations like #DragonCopilot, as AI enabled clinical assistant, clinicians can spend less time on documentation work and more time where it matters most: listening, understanding, and delivering more connected, personalised care. Enabled by better data and AI solutions, women have more agency and a clearer voice to share what impacts them uniquely, differently or disproportionally in their health journeys. At Microsoft, this is part of our AI for Better Health ambition. The next shift is ours: turning awareness into action, and action into better health for women everywhere. #TheShift #WomensHealth #AIforBetterHealth https://lnkd.in/eTUnukXA Jill Seidman Laurette Abou Rjeily Shelley Bransten Larry Jones Rosie Mastrandrea Kees Hertogh Beth De Lisi-Baird Amrutha (Amu) Srinivas Paula Bellostas Muguerza Anna Bode Amanda Riszko Kate Fitzpatrick Dr. Priya Agrawal, MD (BMBCh), MPH Vlada Tusco, Laetitia Nneke, Krystina Meens, Pam Mangat #womenshealth #womenshealthiswHealth #TheShift #wHealthTechManifesto
-
Joshua S. Lev reposted thisJoshua S. Lev reposted thisBioelectronic Medicine is Leveling Up! electroCore, Inc. CEO Dan Goldberger joins us to discuss electroCore (NASDAQ: ECOR) 🚨 Watch the full interview: https://lnkd.in/et7pFCE4 Dan Goldberger, CEO of electroCore, Inc., sits down with us and discusses the company's record-breaking momentum in the bioelectronic medicine space. He confirms that electroCore's 2025 revenue reached approximately $32 million, representing a 26% growth over the previous year. Dan also shares insights into their flagship gammaCore Sapphire™ device and how recent strategic moves—including the acquisition of the Quell® fibromyalgia product line and the expansion of the Truvaga™ wellness brand are accelerating their growth.
-
Joshua S. Lev shared thisJoshua S. Lev shared thisCongrats to Joe McNamara and the rebrand of his leadership development firm The Iron Leader Team! As a former combat-decorated United States Marine Corps infantry officer, his story is inspiring and his team's content is "action oriented, pressure-tested and transformative." Buffalo Groupe guided Joe on a new name, logo, messaging and website. "The quality of your leadership is the single most important factor that will impact the success or failure of an organization. No matter the challenge, developing active iron leaders at every level of your team is the solution." Looking for team building, a keynote speaker, workshop training, etc.? Trusted by NCAA Div. 1 football programs like Clemson University and University of North Carolina at Chapel Hill. https://lnkd.in/gCmZHhDx
-
Joshua S. Lev shared thisZachary Prensky is #hiring. Know anyone who might be interested?
-
Joshua S. Lev shared thisJoshua S. Lev shared thisBustle Review of Truvaga's De-Stressing Vagus Nerve Stimulator - "While Truvaga can take up to a week to work, I honestly felt a little more relaxed after the first try." https://lnkd.in/euaBBqb5Truvaga's Vagus Nerve Stimulator Actually Helps Me Sleep BetterTruvaga's Vagus Nerve Stimulator Actually Helps Me Sleep Better
-
Joshua S. Lev shared thisJoshua S. Lev shared thisCheck out this article highlighting an exciting development in the world of pain management solutions: https://ow.ly/Jct250OYvC9NFL and NFLPA Commit Additional Half Million Dollars to Fund Studies of Innovative Pain Management Solutions, including CBDNFL and NFLPA Commit Additional Half Million Dollars to Fund Studies of Innovative Pain Management Solutions, including CBD
-
Joshua S. Lev shared thisJoshua S. Lev shared thisWe're hiring two Territory Business Managers and an Inside Sales Representative! Join our team and make a difference in the healthcare space. Apply now: https://ow.ly/VIyL50P1zGb #NowHiring #JoinOurTeam #CareerOpportunity #electroCore #MedicalDevice
-
Joshua S. Lev liked thisJoshua S. Lev liked thisI think one of the biggest shifts happening in wellness right now is the growing focus on nervous system health and intentional recovery routines, especially at night. In a world where many people move straight from stress into sleep, creating a consistent nighttime routine can make a real difference by helping the body and mind slow down and reset. That idea inspired our newest collaboration between Truvaga and KORA Organics, centered around Miranda Kerr's evening wellness routine and the role nervous system support can play in winding down. Proud of the team for bringing this to life. Worth checking out if you’re interested in wellness routines, recovery, or nervous system support. 👉 www.truvaga.com
-
Joshua S. Lev liked thisJoshua S. Lev liked thisExcited to see electroCore’s own Dr. Peter Staats presenting at the 17th World Congress of the International Neuromodulation Society in Lisbon this week. Dr. Staats delivered an insightful presentation exploring the evolving role of vagus nerve stimulation and the future of neuromodulation in advancing patient care. It’s inspiring to see these important conversations continuing to shape innovation across the field. Proud to support the groundbreaking work being done to expand awareness and understanding of the vagus nerve and its potential impact on health and resilience. #Neuromodulation #VagusNerve #Innovation #Healthcare #INS2026 #electroCore
-
Joshua S. Lev liked thisJoshua S. Lev liked this"The Vagus Nerve is not a Nerve" ??? "It is the control system for biological resilience" ... Yesterday, we were lucky to attend the OUTSTANDING and GROUNDBREAKING oral presentation by Dr Peter Staats, MD, MBA, Founder and Chairman of the Vagus Nerve Society, at the 17th World Congress of the International Neuromodulation Society held in Lisbon. Thank you Peter! #VNSociety #INS
-
Joshua S. Lev liked thisJoshua S. Lev liked thisPlease join me in welcoming Joe McNamara to Amplify Speakers! Joe builds leaders for high-pressure environments where hesitation has consequences and standards are non-negotiable. A combat-decorated U.S. Marine Corps Ground Force Commander, Joe led Marines through multiple combat deployments before being selected to command and develop the leaders responsible for training the next generation at Marine Corps Recruit Depot Parris Island. In those arenas, leadership was not theoretical. It was immediate. It was tested. And it mattered. From those experiences, Joe developed the Send Me mindset: Prepared. Willing. Decisive. A performance philosophy grounded in a powerful truth. When pressure rises, people do not rise to the level of their ambition. They default to the level of their preparation. After earning his MBA from the University of North Carolina and building an award-winning, high-performing sales organization in the private sector, Joe recognized the same pattern in business and sport. The teams that win under pressure are not simply the most talented. They are the most disciplined, accountable, and decisive when the stakes are highest. Today, as founder of Iron Leader Team, Joe partners with elite athletic programs, executives, and high-performance organizations to build cultures where ownership is expected, communication is clear, and leaders are developed at every level. Joe builds leaders who step forward when responsibility calls. #AmplifySpeakers #Leadership #HighPerformance #Culture #SendMeMindset
-
Joshua S. Lev liked thisJoshua S. Lev liked thisBioelectronic Medicine is Leveling Up! electroCore, Inc. CEO Dan Goldberger joins us to discuss electroCore (NASDAQ: ECOR) 🚨 Watch the full interview: https://lnkd.in/et7pFCE4 Dan Goldberger, CEO of electroCore, Inc., sits down with us and discusses the company's record-breaking momentum in the bioelectronic medicine space. He confirms that electroCore's 2025 revenue reached approximately $32 million, representing a 26% growth over the previous year. Dan also shares insights into their flagship gammaCore Sapphire™ device and how recent strategic moves—including the acquisition of the Quell® fibromyalgia product line and the expansion of the Truvaga™ wellness brand are accelerating their growth.
-
Joshua S. Lev liked thisJoshua S. Lev liked thisToday, I am proud to introduce a project that reflects one of the most defining chapters of my career: Marvel Mindset. In this 10-episode series, I will take you inside Marvel Entertainment’s journey as it emerged from bankruptcy and was ultimately sold to Disney for over $4 billion, sharing the decisions, disciplines, and leadership principles that shaped each step of the turnaround. In Episode 1, I will outline what you can expect from the series and preview the key lessons we will explore together, and in Episode 2, we will begin diving into the early stages of the transformation. Today, we are releasing Episodes 1 and 2, and a new episode will be released every Monday. Full episode: https://lnkd.in/etzniasb #Marvel #MarvelEntertainment #leadership #turnaround #businessturnaround #bankruptcy #podcast
Experience
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Education
-
-
-
-
-
-
-
Other similar profiles
Explore more posts
-
Sebastian Gensior
Royalty financing in biotech and healthcare has grown into a 5 to 6 billion-dollar market in North America, expanding at roughly 45 percent a year since 2018. Ironically, royalty was once a European reserve, and the Americans fought to get rid of it. Now it is booming in the United States while Europe is left with just very few royalty funds. We at Capital for Cures want to change that. Join us in London on November 19 to discuss how Europe can build its own royalty financing ecosystem and bring more non-dilutive capital to its innovators. Read the full article here: https://lnkd.in/eaJMbJCB North America now hosts eight to ten dedicated royalty funds managing over 20 billion dollars in assets. Multi-hundred-million-dollar deals have become routine, while European and Asian firms negotiate under conditions that reflect structural barriers in pricing, tax, and IP systems. The result is a growing financing gap that steers capital toward where markets are comfortable rather than where science is strongest. #Biotech #HealthcareFinance #RoyaltyFinancing #CapitalForCures #VentureCapital #LifeSciences
-
Darin DeWitt
Medtech is having a moment, and the data in both reports suggests it is more than cyclical. Bain puts medtech buyout deal value at an estimated $33 billion in 2025, nearly doubling the prior year, with volume up nearly 20% to 88 deals. Blackstone and TPG's $18.3 billion take-private of Hologic accounted for more than half of that total, and Carlyle's acquisition of Vantive, the renal care business carved out from Baxter, was another signal transaction. Bain notes that medtech has shown outsized growth since 2020 and that investors are successfully deploying proven value-creation playbooks centered on revenue growth, margin expansion, and multiple expansion through carve-outs and public-to-private structures. Healthcare IT produces the highest MOIC in Bain's analysis at 2.3x median, but medtech's 1.9x median and 17% IRR across buyout deals since 2017 reflects a maturing and credible asset class with durable return characteristics, particularly in large-scale transactions where PE ownership adds genuine operational value. McKinsey's operating environment analysis adds the demand context. The shift of care to ambulatory and home settings, expanded ASC procedure approvals, and the Rural Health Transformation Program's $50 billion in technology-linked federal funding all create sustained device and infrastructure demand. On the risk side, Section 232 tariffs and most-favored-nation pricing introduce real cost exposure for manufacturers with global supply chains. The companies that anticipated supply chain localization are structurally better positioned than those responding reactively. The executive talent angle here is one I watch closely. The most sought-after leaders in medtech right now are those who built operational resilience during the COVID-era supply chain dislocation and who have since demonstrated the commercial acuity to drive growth in an ASC and home-care-led market. That combination of supply chain credibility, site-of-care commercial fluency, and technology integration experience is genuinely rare at the platform CEO and COO level.
2 Comments
Explore top content on LinkedIn
Find curated posts and insights for relevant topics all in one place.
View top content